DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining certain parameters in tear fluid. DiagnosTears TeaRx assay is based on various reagents that create color reactions when coming into contact with tear film, allowing for a semi-quantitative assessment of the parameters that define the syndrome. Information on the parameters assists in the diagnosis of the syndrome and enables a better, more informed selection of treatment and monitoring options. TeaRx enables the monitoring and screening of the condition by examining up to five different varieties of tear fluid. The test is carried out through the use of a simple device that is placed under the lower eyelid to absorb the tear fluid. DiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.